Published in AIDS on May 07, 1998
What leads Indians to participate in clinical trials? A meta-analysis of qualitative studies. PLoS One (2010) 3.38
Knowledge and attitudes towards HIV vaccines among Soweto adolescents. BMC Res Notes (2008) 1.72
Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One (2012) 1.64
Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health (2000) 1.47
Use of reality "female condoms" for anal sex by US men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team. Am J Public Health (1999) 1.30
Decisions to participate in research: views of underserved minority drug users with or at risk for HIV. AIDS Care (2008) 1.23
The benefits of participatory methodologies to develop effective community dialogue in the context of a microbicide trial feasibility study in Mwanza, Tanzania. BMC Public Health (2007) 1.19
Retaining hard-to-reach women in HIV prevention and vaccine trials: Project ACHIEVE. Am J Public Health (2001) 1.17
Willingness to participate in HIV-1 vaccine trials among young Thai men. Sex Transm Infect (2000) 1.17
Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Virol (2006) 1.07
HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc (2005) 1.05
Engaging members of African American and Latino communities in preventive HIV vaccine trials. J Acquir Immune Defic Syndr (2009) 1.03
Willingness to participate in HIV/STD prevention activities among Chinese rural-to-urban migrants. AIDS Educ Prev (2004) 1.01
Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine (2013) 0.99
Recruitment of men who have sex with men for large HIV intervention trials: analysis of the EXPLORE Study recruitment effort. AIDS Educ Prev (2010) 0.97
Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial. J Acquir Immune Defic Syndr (2009) 0.94
Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine (2011) 0.94
Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement? Challenge (Atlanta Ga) (2007) 0.93
HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria. AIDS Care (2010) 0.93
Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa? PLoS One (2010) 0.92
Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav (2013) 0.91
Fishermen as a Suitable Population for HIV Intervention Trials. AIDS Res Treat (2010) 0.91
Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. J Acquir Immune Defic Syndr (2013) 0.90
A randomized trial of enhanced HIV risk-reduction and vaccine trial education interventions among HIV-negative, high-risk women who use noninjection drugs: the UNITY study. J Acquir Immune Defic Syndr (2010) 0.89
Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr (2009) 0.87
Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. Hum Vaccin Immunother (2014) 0.85
Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa. Afr Health Sci (2005) 0.85
Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials. Hum Vaccin Immunother (2013) 0.83
In "Step" with HIV Vaccines? A Content Analysis of Local Recruitment Campaigns for an International HIV Vaccine Study. J Health Mass Commun (2009) 0.83
Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine (2010) 0.82
Characteristics of female sex workers in southern India willing and unwilling to participate in a placebo gel trial. AIDS Behav (2013) 0.80
Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs. Drug Alcohol Rev (2012) 0.79
Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine (2014) 0.78
Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B. PLoS One (2016) 0.78
Factors associated with past research participation among low-income persons living with HIV. AIDS Patient Care STDS (2012) 0.78
Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-positive injection drug users. Psychol Health Med (2012) 0.78
Project VOGUE: A partnership for increasing HIV knowledge and HIV vaccine trial awareness among House Ball leaders in Western New York. J Gay Lesbian Soc Serv (2014) 0.77
Typologies of Altruistic and Financial Motivations for Research Participation. J Empir Res Hum Res Ethics (2016) 0.75
Development and evaluation of a web-based assent for adolescents considering an HIV vaccine trial. AIDS Care (2015) 0.75
Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine. Trop Med Surg (2013) 0.75
Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City. Vaccine (2015) 0.75
Building and testing an effective HIV vaccine. West J Med (2000) 0.75
Issues in women's participation in a phase III community HIV vaccine trial in Thailand. AIDS Res Hum Retroviruses (2013) 0.75
Theoretical model of critical issues in informed consent in HIV vaccine trials. AIDS Care (2014) 0.75
The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat (1992) 29.45
MIPS: a database for genomes and protein sequences. Nucleic Acids Res (2002) 11.98
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
A computerised data base for the diagnosis of rare dysmorphic syndromes. J Med Genet (1984) 8.10
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun (1997) 7.87
Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol (2000) 7.77
Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development (1996) 7.00
National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1. Epidemiologic results. Ann Intern Med (1983) 6.67
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci U S A (1996) 6.48
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 6.37
Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res (1999) 6.35
A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell (2000) 6.14
The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A (1997) 6.08
Human leukocyte interferon produced by E. coli is biologically active. Nature (1980) 5.86
HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet (1996) 5.43
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J (2001) 5.29
Genetic analysis of an E. coli strain with a mutation affecting DNA polymerase. Nature (1969) 5.10
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
MIPS: a database for genomes and protein sequences. Nucleic Acids Res (1999) 4.96
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
A case-control study of risk factors for postoperative endophthalmitis. Ophthalmology (1991) 4.83
Risk factors for Kaposi's sarcoma in homosexual men. Lancet (1982) 4.70
A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis (1992) 4.64
The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (1984) 4.61
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature (1981) 4.50
Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem (2000) 4.15
Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell (1984) 3.81
Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med (1990) 3.80
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A (1995) 3.68
Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sex Transm Dis (2000) 3.60
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J (1990) 3.59
Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA (1994) 3.41
Adult survivors of childhood sexual abuse and subsequent risk of HIV infection. Am J Public Health (1991) 3.30
The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J (1989) 3.23
Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther (2001) 2.95
Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet (2007) 2.91
The Circuit Party Men's Health Survey: findings and implications for gay and bisexual men. Am J Public Health (2001) 2.83
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev (2001) 2.74
HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health (2000) 2.74
Interferon-associated retinopathy. Arch Ophthalmol (1993) 2.73
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses (1994) 2.62
Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A (2001) 2.61
Molecular cloning and nucleotide sequence of the type I beta-lactamase gene from Bacillus cereus. Nucleic Acids Res (1983) 2.61
Marriage, monogamy and HIV: a profile of HIV-infected women in south India. Int J STD AIDS (2000) 2.59
Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr (2001) 2.59
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation (2000) 2.49
Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science (1985) 2.44
Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol (2001) 2.41
Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature (2000) 2.41
The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology (2009) 2.33
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31
A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med (1991) 2.30
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health (1998) 2.28
Sexual violence against women living with or at risk for HIV infection. Am J Prev Med (1997) 2.26
Retracted Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol Cell Biol (1999) 2.25
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr (2000) 2.22
The Longitudinal Assessment of Imaging and Disability of the Back (LAIDBack) Study: baseline data. Spine (Phila Pa 1976) (2001) 2.21
A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City. Science (1988) 2.20
Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome. Proc Natl Acad Sci U S A (1988) 2.20
Orthostatic hypotension in Parkinson's disease. Lancet (1972) 2.19
Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health (1992) 2.16
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect (2006) 2.14
SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol Cell Biol (1997) 2.14
Emotional, behavioral, and HIV risks associated with sexual abuse among adult homosexual and bisexual men. Child Abuse Negl (1994) 2.09
Treatment of acute polyneuropathy by plasma exchange. Lancet (1978) 2.06
Self-destructing (non-reusable) syringes. Lancet (1991) 2.04
Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust (1989) 2.02
Additional evidence that the hemin-controlled translational repressor from rabbit reticulocytes is a protein kinase. Biochem Biophys Res Commun (1977) 2.01
Temporally controlled somatic mutagenesis in smooth muscle. Genesis (2000) 2.01
Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis (1996) 2.00
Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic. Sex Transm Dis (2000) 2.00
Spontaneous pneumothorax and mitral valve prolapse. Chest (1986) 1.99
Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J (1993) 1.99
Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat (1998) 1.98
Human fibroblast interferon gene lacks introns. Nucleic Acids Res (1981) 1.98
Circumcision and STD in the United States: cross sectional and cohort analyses. Sex Transm Infect (2000) 1.94